Detailansicht

Wissensnetz

Person

Markus Hoffmann

Biologe

Name	Markus Hoffmann
Ort	Deutschland
Geschlecht	männlich
Akademischer Grad bzw. Titel	Dr. rer. nat.
Beruf	Biologe (charakteristischer Beruf)
Beziehung	Deutsches Primatenzentrum GmbH, Leibniz-Institut für Primatenforschung, Göttingen
Datensatztyp	Person
GND-Nummer	1310034265
Datensatz-ID	1310034265
Beteiligt an alle anzeigen Phosphatidylserine-exposing extracellular vesicles in body fluids are an innate defence against apoptotic mimicry viral pathogens Omicron spike protein: a clue for viral entry and immune evasion Publisher Correction: Dalbavancin: novel candidate for COVID-19 treatment BNT162b2-boosted immune responses six months after heterologous or homologous ChAdOx1nCoV-19/BNT162b2 vaccination against COVID-19 Peptidomimetic inhibitors of TMPRSS2 block SARS-CoV-2 infection in cell culture Efficient antibody evasion but reduced ACE2 binding by the emerging SARS-CoV-2 variant B.1.640.2 Long-term immune protection against SARS-CoV-2 escape variants upon a single vaccination with murine cytomegalovirus expressing the spike protein Dalbavancin: novel candidate for COVID-19 treatment Low serum neutralizing anti-SARS-CoV-2 S antibody levels in mildly affected COVID-19 convalescent patients revealed by two different detection methods LY6E impairs coronavirus fusion and confers immune control of viral disease Functional analysis of potential cleavage sites in the MERS-coronavirus spike protein

Hinweis

Die Betaversion beinhaltet noch nicht alle Funktionen und Informationen des Katalogs des DNB-Portals. Falls Sie Informationen vermissen oder ein Medium bestellen wollen, besuchen Sie bitte die entsprechende Seite im Katalog des DNB-Portals über folgenden Link:

Katalog der Deutschen Nationalbibliothek

Markus Hoffmann

Phosphatidylserine-exposing extracellular vesicles in body fluids are an innate defence against apoptotic mimicry viral pathogens

Omicron spike protein: a clue for viral entry and immune evasion

Publisher Correction: Dalbavancin: novel candidate for COVID-19 treatment

BNT162b2-boosted immune responses six months after heterologous or homologous ChAdOx1nCoV-19/BNT162b2 vaccination against COVID-19

Peptidomimetic inhibitors of TMPRSS2 block SARS-CoV-2 infection in cell culture

Efficient antibody evasion but reduced ACE2 binding by the emerging SARS-CoV-2 variant B.1.640.2

Long-term immune protection against SARS-CoV-2 escape variants upon a single vaccination with murine cytomegalovirus expressing the spike protein

Dalbavancin: novel candidate for COVID-19 treatment

Low serum neutralizing anti-SARS-CoV-2 S antibody levels in mildly affected COVID-19 convalescent patients revealed by two different detection methods

LY6E impairs coronavirus fusion and confers immune control of viral disease

Functional analysis of potential cleavage sites in the MERS-coronavirus spike protein